Sobi's Kineret approved in US for neonatal-onset multisystem inflammatory disease
This article was originally published in Scrip
Executive Summary
The US FDA has approved Swedish Orphan Biovitrum's (Sobi) recombinant protein product, Kineret (anakinra), for the treatment of children and adults with neonatal-onset multisystem inflammatory disease (NOMID), making it the first and only FDA-approved therapy for this most severe form of cryopyrin associated periodic syndromes (CAPS), the company noted.